The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Agendia; Agendia; Agendia; Agendia; Amgen; Amgen; Amgen; Amgen; Aristo; Aristo; Aristo; Aristo; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Carl Zeiss Meditec; Carl Zeiss Meditec; Carl Zeiss Meditec; Carl Zeiss Meditec; Celgene; Celgene; Celgene; Celgene; ClinSol; ClinSol; ClinSol; ClinSol; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Genomic Health; Genomic Health; Genomic Health; Genomic Health; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Hexal; Hexal; Hexal; Hexal; Lilly; Lilly; Lilly; Lilly; Medstrom Medical; Medstrom Medical; Medstrom Medical; Medstrom Medical; MSD; MSD; MSD; MSD; Mundipharma; Mundipharma; Mundipharma; Mundipharma; NanoString Technologies; NanoString Technologies; NanoString Technologies; NanoString Technologies; Novartis; Novartis; Novartis; Novartis; Odonate Therapeutics; Odonate Therapeutics; Odonate Therapeutics; Odonate Therapeutics; Palleos; Palleos; Palleos; Palleos; Paxman; Paxman; Paxman; Paxman; Pfizer; Pfizer; Pfizer; Pfizer; Pi; Pierre Fabre; Pierre Fabre; Pierre Fabre
Speakers' Bureau - Agendia; Agendia; Agendia; Agendia; Amgen; Amgen; Amgen; Amgen; Aristo; Aristo; Aristo; Aristo; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Carl Zeiss Meditec; Carl Zeiss Meditec; Carl Zeiss Meditec; Carl Zeiss Meditec; Celgene; Celgene; Celgene; Celgene; ClinSol; ClinSol; ClinSol; ClinSol; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Genomic Health; Genomic Health; Genomic Health; Genomic Health; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Hexal; Hexal; Hexal; Hexal; Lilly; Lilly; Lilly; Lilly; Medstrom Medical; Medstrom Medical; Medstrom Medical; Medstrom Medical; MSD; MSD; MSD; MSD; Mundipharma; Mundipharma; Mundipharma; Mundipharma; NanoString Technologies; NanoString Technologies; NanoString Technologies; NanoString Technologies; Novartis; Novartis; Novartis; Novartis; Odonate Therapeutics; Odonate Therapeutics; Odonate Therapeutics; Odonate Therapeutics; Palleos; Palleos; Palleos; Palleos; Paxman; Paxman; Paxman; Paxman; Pfizer; Pfizer; Pfizer; Pfizer; Pi; Pierre Fabre; Pierre Fabre; Pierre Fabre
Travel, Accommodations, Expenses - Agendia; Agendia; Agendia; Agendia; Amgen; Amgen; Amgen; Amgen; Aristo; Aristo; Aristo; Aristo; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Carl Zeiss Meditec; Carl Zeiss Meditec; Carl Zeiss Meditec; Carl Zeiss Meditec; Celgene; Celgene; Celgene; Celgene; ClinSol; ClinSol; ClinSol; ClinSol; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Genomic Health; Genomic Health; Genomic Health; Genomic Health; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Hexal; Hexal; Hexal; Hexal; Lilly; Lilly; Lilly; Lilly; Medstrom Medical; Medstrom Medical; Medstrom Medical; Medstrom Medical; MSD; MSD; MSD; MSD; Mundipharma; Mundipharma; Mundipharma; Mundipharma
Substantial ninety-nine percent reduction of turnaround time for QTc diagnostics using smartphone-based tele-cardiology.
 
Lena-Sophie Fink
Employment - CANKADO
 
Timo Schinkoethe
Leadership - CANKADO
Stock and Other Ownership Interests - CANKADO
 
Rachel Wuerstlein
No Relationships to Disclose
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)